Topic has been suspended
Status Suspended
Process STA 2018
ID number 1597


Key events during the development of the guidance:

Date Update
17 April 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia. Following a recent update from the company, NICE has decided to suspend this appraisal on its work programme. As the appraisal has been referred, NICE will continue to monitor any developments and will provide a further update in due course.
17 April 2020 Suspended. Topic has been suspended
10 May 2019 In progress. Referred 13 February 2018

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance